Financials

News Ideas Discussions Technicals Seasonals

ALA fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Arovella Therapeutics Ltd. engages in the development invariant Natural Killer (iNKT) cell platform for treatment of cancer. Its technologies include iNKT cell therapy, CAR19-iNKT + CF33-CD19, CLDN18.2-iNKT, and DKK1-CAR-iNKT. The company was founded on December 21, 1999 and is headquartered in Carlton South, Australia.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

ALA has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company